A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence DOI Creative Commons
Xuwen Liu, Hongyan Chen, Guirong Tan

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 28, 2024

Cancer immunotherapy has emerged as a novel clinical therapeutic option for variety of solid tumors over the past decades. The application in primary and metastatic brain continues to grow despite limitations due physiological characteristics immune system within central nervous (CNS) distinct pathological barriers malignant tumors. post-immunotherapy treatment imaging is more complex. In this review, we summarize immunotherapies beyond CNS. We provide an overview current used tumors, including checkpoint inhibitors (ICIs), oncolytic viruses, vaccines, CAR T-cell therapies. focus on criteria assessment response immunotherapy, patterns. discuss advanced techniques evaluation treatment-related complications CNS are described. Lastly, future challenges field explored.

Language: Английский

Differential Replication and Oncolytic Effects of Zika Virus in Aggressive CNS Tumor Cells: Insights from Organoid and Tumoroid Models DOI Creative Commons
Rodolfo Sanches Ferreira, Elisa Helena Farias Jandrey, Isabela Granha

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(11), P. 1764 - 1764

Published: Nov. 12, 2024

Central nervous system (CNS) cancers are responsible for high rates of morbidity and mortality worldwide. Malignant CNS tumors such as adult Glioblastoma (GBM) pediatric embryonal medulloblastoma (MED) atypical teratoid rhabdoid (ATRT) present relevant therapeutic challenges due to the lack response classic treatment regimens with radio chemotherapy. Recent findings on Zika virus’ (ZIKV) ability infect kill neoplastic cells draw attention oncolytic potential. Studies demonstrating safety using ZIKV treating malignant tumors, enabling translation this approach clinical trials, scarce in literature. Here we developed a co-culture model mature human cerebral organoids assembled GBM, MED or ATRT tumor used these assembloids test effect, replication potential preferential targeting between normal cancer cells. Our hybrid models allowed tracking cell growth invasion organoids. ensuing accumulation culture medium was higher co-cultured than isolated control without infection led significant reduction proportion GBM cells, but not ATRT. Tumoroids (3D cultures alone) were efficiently infected by ZIKV. Interestingly, rapidly replicated MED, tumoroids reaching significantly viral RNA levels co-cultures. Moreover, reduced viable number tumoroids. Altogether, our indicate that has greater aggressive comprising However, does necessarily parallels effects, suggesting cellular intrinsic extrinsic factors mediating death

Language: Английский

Citations

3

Forms of Non-Apoptotic Cell Death and Their Role in Gliomas—Presentation of the Current State of Knowledge DOI Creative Commons
Reinhold Nafe, Elke Hattingen

Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1546 - 1546

Published: July 11, 2024

In addition to necrosis and apoptosis, the two forms of cell death that have been known for many decades, other non-apoptotic discovered, which also play a role in tumors. Starting with description autophagy more than 60 years ago, newer become important biology tumors, such as ferroptosis, pyroptosis, necroptosis, paraptosis. this review, all oncologically relevant programmed are presented, starting their first descriptions, molecular characteristics, interactions physiology pathophysiology. Based on these current state knowledge about alterations gliomas will be presented. addition, efforts therapeutically influence components discussed. Although research into exact is still at rather early stage, our review clarifies show significant insight understanding them has already gained.

Language: Английский

Citations

2

Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy DOI Creative Commons
Ludovica Gaiaschi, Maria Grazia Bottone, Fabrizio De Luca

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(12), P. 14324 - 14350

Published: Dec. 19, 2024

Glioblastoma multiforme (GBM) is one of the most aggressive and difficult-to-treat brain tumors, with a poor prognosis due to its high resistance conventional therapies. Current treatment options, including surgical resection, radiotherapy, chemotherapy, have limited effectiveness in improving long-term survival. Despite emergence new therapies, monotherapy approaches not shown significant improvements, highlighting need for innovative therapeutic strategies. Combination therapies appear be promising solution, as they target multiple molecular pathways involved GBM progression. One area growing interest incorporation phytotherapy micotherapy complementary treatments, which offer potential benefits their anti-tumor, anti-inflammatory, immunomodulatory properties. This review examines current challenges treatment, discusses combination highlights role integrative options management.

Language: Английский

Citations

2

A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence DOI Creative Commons
Xuwen Liu, Hongyan Chen, Guirong Tan

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 28, 2024

Cancer immunotherapy has emerged as a novel clinical therapeutic option for variety of solid tumors over the past decades. The application in primary and metastatic brain continues to grow despite limitations due physiological characteristics immune system within central nervous (CNS) distinct pathological barriers malignant tumors. post-immunotherapy treatment imaging is more complex. In this review, we summarize immunotherapies beyond CNS. We provide an overview current used tumors, including checkpoint inhibitors (ICIs), oncolytic viruses, vaccines, CAR T-cell therapies. focus on criteria assessment response immunotherapy, patterns. discuss advanced techniques evaluation treatment-related complications CNS are described. Lastly, future challenges field explored.

Language: Английский

Citations

1